Shukra Pharmaceuticals Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 13/11/2025 ,inter alia, to consider and approve As attached
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Shukra Pharmaceuticals has informed BSE that its Board of Directors will meet on Thursday, 13 November 2025 at the registered office in Ahmedabad. The main agenda is to consider and approve the unaudited financial results for the half year ended 30 September 2025, along with the Auditor's Limited Review Report. Any other business items may be taken up with the Chairman's permission. This is a standard pre-results intimation filed under SEBI LODR Regulation 29.
No immediate impact on shareholders — this is a routine procedural disclosure. Investors should watch for the actual H1 FY26 results announcement after 13 November 2025 for any meaningful business signals, as no financial figures are disclosed here.